BiotechTube

ARS-1 with URTI + ARS-1 without URTI

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Upper Respiratory Tract Infection

Conditions

Upper Respiratory Tract Infection

Trial Timeline

Aug 9, 2021 → Jul 25, 2022

NCT ID
NCT04930900

About ARS-1 with URTI + ARS-1 without URTI

ARS-1 with URTI + ARS-1 without URTI is a phase 1 stage product being developed by ARS Pharmaceuticals for Upper Respiratory Tract Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT04930900. Target conditions include Upper Respiratory Tract Infection.

What happened to similar drugs?

6 of 15 similar drugs in Upper Respiratory Tract Infection were approved

Approved (6) Terminated (1) Active (9)
✅Remimazolam TosilateJiangsu Hengrui MedicineApproved
✅BOTOXAbbVieApproved
✅Montelukast + PlaceboMerckApproved
✅diclofenac potassium + nimesulideNovartisApproved
✅Diclofenac gelNovartisApproved
✅AboBoNT-A + OnaBoNT-AIpsenApproved
🔄Muntelukast + PlaceboMerckPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04930900Phase 1Completed

Competing Products

20 competing products in Upper Respiratory Tract Infection

See all competitors
ProductCompanyStageHype Score
Nivolumab 100 MG in 10 ML InjectionOno PharmaceuticalPhase 2
31
Remimazolam TosilateJiangsu Hengrui MedicineApproved
43
ABBV-950 + BOTOX + Placebo for ABBV-950AbbViePhase 1
21
BOTOX + Placebo for BOTOXAbbViePhase 2
35
BOTOXAbbVieApproved
43
MK-3475 and BCGMerckPhase 2
42
Montelukast + PlaceboMerckApproved
43
Muntelukast + PlaceboMerckPhase 3
36
IFF flavor 316 282, Paracetamol, PseudoephedrineNovartisPhase 3
40
Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets + Paracetamol (500 mg) tabletsNovartisPhase 3
40
diclofenac potassium + nimesulideNovartisApproved
35
Diclofenac gelNovartisApproved
43
IFF flavor 316 282, Paracetamol , Phenylephrine, GuaifenesinNovartisPhase 3
40
Domvanalimab + Zimberelimab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin + NivolumabGilead SciencesPhase 3
44
Azithromycin SRPfizerPhase 3
40
NivolumabBristol Myers SquibbPre-clinical
26
NivolumabBristol Myers SquibbPre-clinical
26
REGN475/SAR164877 + Placebo (for REGN475/SAR164877)Regeneron PharmaceuticalsPhase 2
27
IPN10200 + IPN10200 Placebo + DysportIpsenPhase 1/2
36
AboBoNT-A + OnaBoNT-AIpsenApproved
40